<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="1269">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on February 08, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04406038</url>
  </required_header>
  <id_info>
    <org_study_id>CDRU-001</org_study_id>
    <nct_id>NCT04406038</nct_id>
  </id_info>
  <brief_title>Study of the Spread of COVID-19 in Saint Petersburg, Russia</brief_title>
  <official_title>A Population-Based Seroprevalence of SARS-CoV-2-Specific Antibodies Among Adults in Saint Petersburg, Russia: Longitudinal Cohort Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>European University at St. Petersburg</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>European University at St. Petersburg</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Seroprevalence study of COVID-19 in Saint Petersburg, Russia is a regional longitudinal&#xD;
      cohort study aiming to evaluate the spread dynamics of the COVID-19 disease in the population&#xD;
      of Saint Petersburg. Clinically asymptomatic adults are sampled from the population using&#xD;
      random digit dialing and tested for the presence of SARS-CoV-2-specific antibodies in the&#xD;
      blood serum. Data collection and serial sampling of the same individuals spans four weeks and&#xD;
      is conducted every two weeks in order to understand both the spread of the virus in the&#xD;
      population.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      At least 1 000 individuals, 18 years old and older, are randomly sampled using random digit&#xD;
      dialing from the population of Saint Petersburg, Russia. Random sampling is performed by a&#xD;
      survey company on the list of mobile phone numbers with designated geography prefixes of St.&#xD;
      Petersburg. The baseline questionnaire for computer-assisted telephone interview includes&#xD;
      travel history, medical history, and socio-economic status of the respondents. Sampled&#xD;
      individuals are then invited to the clinic for blood sampling, their refusal to participate&#xD;
      is recorded. Collected blood samples are used for SARS-CoV-2-specific antibodies testing.&#xD;
      Data and sample collection spans four weeks and is conducted every two weeks. Participants&#xD;
      complete additional questionnaires in the clinic providing information on medical history,&#xD;
      history of allergies, chronic disease, smoking, and medication taken regularly. Contact&#xD;
      tracing data and environmental conditions of the household are re—Åorded.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">May 27, 2020</start_date>
  <completion_date type="Anticipated">October 28, 2021</completion_date>
  <primary_completion_date type="Anticipated">October 28, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Prevalence of the SARS-COV-2 infection in Saint Petersburg, Russia</measure>
    <time_frame>Measured with two-week (14 days) intervals</time_frame>
    <description>Measured by SARS-CoV-2-specific antibodies serial testing and corrected for volunteer bias and test characteristics.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Prevalence odds ratios</measure>
    <time_frame>Measured with two-week (14 days) intervals</time_frame>
    <description>Comparison of prevalence by age, sex and socioeconomic strata.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immune response dynamics</measure>
    <time_frame>Measured with two-week (14 days) intervals</time_frame>
    <description>Seropositivity, seroreversion and seroconversion.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">1038</enrollment>
  <condition>COVID19</condition>
  <arm_group>
    <arm_group_label>Healthy adults</arm_group_label>
    <description>Healthy adults randomly sampled from the population of Saint Petersburg</description>
  </arm_group>
  <eligibility>
    <study_pop>
      <textblock>
        Representative sample of the population of Saint Petersburg, Russia&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Individuals sampled from the population of Saint Petersburg, Russia using random digit&#xD;
             dialling.&#xD;
&#xD;
          -  Subjects aged 18 and older of both genders.&#xD;
&#xD;
          -  Asymptomatic at the time of blood draw.&#xD;
&#xD;
          -  Written informed consent for a blood draw, SARS-COV-2 antibody test, and data&#xD;
             collection.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of fever or cough or respiratory distress at the time of blood test not&#xD;
             attributable to other known chronic disease.&#xD;
&#xD;
          -  Age under 18.&#xD;
&#xD;
          -  Any health condition that may be a contraindication towards blood sampling in&#xD;
             out-patient clinic.&#xD;
&#xD;
          -  Residence in Kolpinskiy, Kurortniy, Krasnoselsky, Kronshtadtskiy, Petrodvorcoviy,&#xD;
             Pushkinskiy districts of St. Petersburg.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lubov Barabanova, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Clinic &quot;Scandinavia&quot;</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinic &quot;Scandinavia&quot;</name>
      <address>
        <city>Saint Petersburg</city>
        <zip>196084</zip>
        <country>Russian Federation</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Russian Federation</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>May 26, 2020</study_first_submitted>
  <study_first_submitted_qc>May 26, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">May 28, 2020</study_first_posted>
  <last_update_submitted>February 2, 2021</last_update_submitted>
  <last_update_submitted_qc>February 2, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 3, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>seroprevalence</keyword>
  <keyword>covid-19</keyword>
  <keyword>sars-cov-2</keyword>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Anonymized individual phone survey data, anonymized paper-based survey data, test results, and analytic code are available in a designated repository (see the URL below).</ipd_description>
    <ipd_info_type>Analytic Code</ipd_info_type>
    <ipd_time_frame>Currently available and for indefinite period</ipd_time_frame>
    <ipd_access_criteria>Creative Commons License Attribution 4.0 International (CC BY 4.0)</ipd_access_criteria>
    <ipd_url>https://github.com/eusporg/spb_covid_study20</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Informed Consent Form</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>Yes</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>July 15, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/38/NCT04406038/Prot_ICF_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

